Athersys Company Profile (NASDAQ:ATHX)

About Athersys

Athersys logoAthersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ATHX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.18
  • 50 Day Moving Average: $1.29
  • 200 Day Moving Average: $1.70
  • 52-Week Range: $1.02 - $2.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.00
  • P/E Growth: -0.23
  • Market Cap: $101.74M
  • Outstanding Shares: 85,498,000
  • Beta: -0.17
Profitability:
  • Net Margins: -17.12%
  • Return on Equity: -22.82%
  • Return on Assets: -16.90%
Debt:
  • Current Ratio: 3.98%
  • Quick Ratio: 3.98%
Additional Links:
Companies Related to Athersys:

Analyst Ratings

Consensus Ratings for Athersys (NASDAQ:ATHX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50 (608.33% upside)

Analysts' Ratings History for Athersys (NASDAQ:ATHX)
Show:
DateFirmActionRatingPrice TargetDetails
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00View Rating Details
11/12/2016Maxim GroupSet Price TargetBuy$10.00View Rating Details
1/10/2016WBB SecuritiesReiterated RatingBuy$9.00View Rating Details
7/10/2015Piper Jaffray CompaniesDowngradeOverweight -> HoldView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Athersys (NASDAQ:ATHX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/9/2016Q3 2016($0.10)($0.07)$0.60 million$0.31 millionViewListenView Earnings Details
8/9/2016Q216($0.10)($0.08)$0.32 million$0.60 millionViewN/AView Earnings Details
5/5/2016Q1($0.08)$0.06$1.85 million$15.45 millionViewN/AView Earnings Details
3/10/2016Q4($0.09)$0.04$3.72 million$10.61 millionViewListenView Earnings Details
11/5/2015Q315($0.07)($0.08)$1.75 million$0.40 millionViewListenView Earnings Details
8/6/2015Q2($0.08)($0.05)$2.66 million$0.22 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.16)$2.01 million$0.73 millionViewListenView Earnings Details
3/12/2015Q414($0.10)($0.08)$0.50 million$0.24 millionViewN/AView Earnings Details
11/10/2014Q314($0.09)($0.06)$0.54 million$0.29 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)$0.01$0.70 million$0.40 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.09)$0.66 million$0.71 millionViewN/AView Earnings Details
3/13/2014Q413($0.11)($0.15)$1.81 million$0.92 millionViewN/AView Earnings Details
11/14/2013Q3($0.12)($0.10)$0.49 million$0.62 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.12)($0.11)$390.00 million$0.57 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.11)($0.18)$1.58 million$0.33 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.12)$2.51 million$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Athersys (NASDAQ:ATHX)
Current Year EPS Consensus Estimate: $-0.18 EPS
Next Year EPS Consensus Estimate: $-0.30 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.05)($0.05)($0.05)
Q2 20161($0.09)($0.09)($0.09)
Q3 20161($0.11)($0.11)($0.11)
Q4 20161($0.11)($0.11)($0.11)
Q1 20171($0.07)($0.07)($0.07)
Q2 20171($0.07)($0.07)($0.07)
Q3 20171($0.07)($0.07)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Athersys (NASDAQ:ATHX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Athersys (NASDAQ:ATHX)
Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 17.24%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2017Ismail KolaDirectorBuy15,000$1.01$15,150.00View SEC Filing  
2/1/2017Laura K CampbellInsiderBuy20,000$1.01$20,200.00View SEC Filing  
12/19/2016William Lehmann JrInsiderSell3,000$1.60$4,800.00View SEC Filing  
12/16/2016John J HarringtonEVPSell15,000$1.60$24,000.00View SEC Filing  
9/19/2016William Lehmann JrInsiderSell3,000$1.96$5,880.00View SEC Filing  
9/16/2016John J HarringtonEVPSell15,000$1.96$29,400.00View SEC Filing  
6/21/2016William Lehmann JrCOOSell25,000$2.17$54,250.00View SEC Filing  
3/21/2016William Lehmann JrCOOSell25,000$2.41$60,250.00View SEC Filing  
12/21/2015William Lehmann, Jr.COOSell25,000$1.03$25,750.00View SEC Filing  
9/21/2015Bokkelen Gil VanCEOSell9,500$1.36$12,920.00View SEC Filing  
9/21/2015John J. HarringtonEVPSell8,150$1.36$11,084.00View SEC Filing  
9/21/2015William Lehmann, Jr.COOSell25,000$1.36$34,000.00View SEC Filing  
6/22/2015William Lehmann JrCOOSell25,000$1.21$30,250.00View SEC Filing  
6/19/2015John J HarringtonInsiderSell8,150$1.23$10,024.50View SEC Filing  
6/19/2015Robert J DeansEVPSell5,080$1.23$6,248.40View SEC Filing  
6/9/2015Kenneth H TraubDirectorBuy30,000$1.27$38,100.00View SEC Filing  
3/20/2015William Lehmann JrCOOSell25,000$3.14$78,500.00View SEC Filing  
3/19/2015Bokkelen Gil VanCEOSell9,500$3.10$29,450.00View SEC Filing  
3/19/2015Robert J DeansEVPSell5,080$3.10$15,748.00View SEC Filing  
12/19/2014Bokkelen Gil VanCEOSell9,500$1.29$12,255.00View SEC Filing  
12/19/2014Robert J DeansEVPSell5,080$1.28$6,502.40View SEC Filing  
12/19/2014William Lehmann JrCOOSell30,000$1.29$38,700.00View SEC Filing  
9/24/2014Kenneth H TraubDirectorBuy30,000$1.39$41,700.00View SEC Filing  
9/22/2014William Lehmann JrCOOSell30,000$1.40$42,000.00View SEC Filing  
9/19/2014Bokkelen Gil VanCEOSell9,500$1.41$13,395.00View SEC Filing  
9/19/2014John J HarringtonInsiderSell8,150$1.41$11,491.50View SEC Filing  
9/19/2014Robert J DeansEVPSell5,080$1.41$7,162.80View SEC Filing  
8/18/2014Lorin RandallDirectorSell15,000$1.54$23,100.00View SEC Filing  
6/20/2014William Lehmann JrCOOSell12,000$1.58$18,960.00View SEC Filing  
6/19/2014Bokkelen Gil VanCEOSell9,500$1.63$15,485.00View SEC Filing  
6/19/2014John J HarringtonInsiderSell8,150$1.63$13,284.50View SEC Filing  
6/19/2014Robert J DeansEVPSell5,080$1.63$8,280.40View SEC Filing  
6/19/2014William Lehmann JrCOOSell13,000$1.62$21,060.00View SEC Filing  
3/20/2014William Lehmann JrCOOSell25,000$3.62$90,500.00View SEC Filing  
3/18/2014Bokkelen Gil VanCEOSell9,500$3.54$33,630.00View SEC Filing  
3/18/2014John J HarringtonInsiderSell8,150$3.54$28,851.00View SEC Filing  
3/18/2014Robert J DeansEVPSell5,080$3.54$17,983.20View SEC Filing  
12/20/2013William Lehmann JrCOOSell25,000$2.13$53,250.00View SEC Filing  
12/11/2013Kenneth H TraubDirectorBuy20,000$1.94$38,800.00View SEC Filing  
9/20/2013John J HarringtonInsiderSell30,000$1.82$54,600.00View SEC Filing  
9/20/2013William Lehmann JrCOOSell12,000$1.83$21,960.00View SEC Filing  
11/28/2012Laura K CampbellVPBuy10,000$1.01$10,100.00View SEC Filing  
11/15/2012Robert J DeansEVPBuy3,500$0.99$3,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Athersys (NASDAQ:ATHX)
DateHeadline
News IconInvestor Watch on Shares of Athersys, Inc. (NASDAQ:ATHX) - SKV News (NASDAQ:ATHX)
skvnews.com - February 24 at 11:17 PM
News IconStock Watch: Examining the Levels on Shares of Athersys, Inc. (NASDAQ:ATHX) - Baldwin Journal (NASDAQ:ATHX)
baldwinjournal.com - February 24 at 11:17 PM
News IconFocusing the Lens on Athersys, Inc. (NASDAQ:ATHX) Earnings & Projections - Winfield Review (NASDAQ:ATHX)
winfieldreview.com - February 24 at 11:17 PM
News IconAre Analysts Optimistic About Where Athersys, Inc. (NASDAQ:ATHX) is Heading? - Winfield Review (NASDAQ:ATHX)
winfieldreview.com - February 24 at 11:17 PM
News IconAnalysts Peeling Back The Layers on Athersys, Inc. (NASDAQ:ATHX): Consensus Take - Winfield Review (NASDAQ:ATHX)
winfieldreview.com - February 23 at 8:43 PM
feeds.benzinga.com logoOverview of MultiStem® Clinical Trial in Japan Presentation at International Stroke Conference 2017 (NASDAQ:ATHX)
feeds.benzinga.com - February 23 at 7:42 AM
News IconAthersys, Inc. (NASDAQ:ATHX) Earnings At A Glance: Consensus Projections in Spotlight - Winfield Review (NASDAQ:ATHX)
winfieldreview.com - February 22 at 3:39 PM
News IconThe Technical Charts For Athersys, Inc. (ATHX) Say It All Today - NY Stock News (NASDAQ:ATHX)
nystocknews.com - February 22 at 3:39 PM
News IconInsider Update on Athersys, Inc. (NASDAQ:ATHX) - Winfield Review (NASDAQ:ATHX)
winfieldreview.com - February 21 at 9:46 AM
News IconWhat is the Street Saying About Athersys, Inc. (NASDAQ:ATHX)? - Aiken Advocate (NASDAQ:ATHX)
aikenadvocate.com - February 21 at 9:46 AM
News IconFocusing on the Numbers for Athersys, Inc. (NASDAQ:ATHX) - SKV News (NASDAQ:ATHX)
skvnews.com - February 18 at 9:46 AM
News IconEarnings at a Glance For Athersys, Inc. (NASDAQ:ATHX): What Are Analysts Predicting For the Stock? - Winfield Review (NASDAQ:ATHX)
winfieldreview.com - February 18 at 9:46 AM
News IconPeeling Back The Layers on Athersys, Inc. (NASDAQ:ATHX): Analysts & Street Weigh In - Winfield Review (NASDAQ:ATHX)
winfieldreview.com - February 14 at 9:21 PM
finance.yahoo.com logoAthersys to Host Year-End 2016 Financial Results Call (NASDAQ:ATHX)
finance.yahoo.com - February 14 at 4:20 PM
News IconWhat are Research Firms Saying About Athersys, Inc. (NASDAQ:ATHX)? - Aiken Advocate (NASDAQ:ATHX)
aikenadvocate.com - February 14 at 2:13 AM
News IconHot Stocks – FireEye Inc (NASDAQ:FEYE), Athersys, Inc. (NASDAQ ... - Financial Breaking News (NASDAQ:ATHX)
wsbreakingnews.com - February 8 at 3:16 PM
istreetwire.com logoTrader Alert: Athersys, Inc. (ATHX), Allegheny Technologies ... - iStreetWire (NASDAQ:ATHX)
istreetwire.com - February 8 at 3:16 PM
News IconWhich analysts are covering Athersys, Inc. (ATHX)? - Post Analyst (NASDAQ:ATHX)
postanalyst.com - February 8 at 3:16 PM
News IconZooming in on Stock Levels: Athersys Inc. (ATHX) - Rives Journal (NASDAQ:ATHX)
rivesjournal.com - February 7 at 4:37 PM
News IconAthersys, Inc. (ATHX) stock starts with “Buy” rating in note to investors by Needham & Company LLC - The Ledger Gazette (NASDAQ:ATHX)
ledgergazette.com - February 7 at 4:37 PM
finance.yahoo.com logoCoverage initiated on Athersys by Needham (NASDAQ:ATHX)
finance.yahoo.com - February 7 at 4:37 PM
News IconTenax Therapeutics Inc (NASDAQ:TENX) Stock Technicals Hit Extreme Weakness (NASDAQ:ATHX)
jagsreport.com - February 2 at 1:52 AM
marketexclusive.com logoATHERSYS, INC. (NASDAQ:ATHX) Files An 8-K Other Events - Market Exclusive (NASDAQ:ATHX)
marketexclusive.com - February 1 at 8:50 PM
finance.yahoo.com logoAthersys Announces Closing of Public Offering of Common Stock (NASDAQ:ATHX)
finance.yahoo.com - February 1 at 8:50 PM
News IconInvestments Worthy Stocks: Akorn, Inc. (NASDAQ:AKRX), Athersys, Inc. (NASDAQ:ATHX) - Street Wise Report (press release) (blog) (NASDAQ:ATHX)
streetwisereport.com - February 1 at 3:49 PM
News IconAre Analysts Forecasting a Near-Term Upswing For Athersys, Inc. (NASDAQ:ATHX)? - Wall Street Beacon (NASDAQ:ATHX)
wsbeacon.com - February 1 at 3:49 PM
News IconAthersys, Inc. (NASDAQ:ATHX) Insider Trading Review | Newburgh ... - The Newburgh Press (NASDAQ:ATHX)
newburghpress.com - February 1 at 3:49 PM
News IconEarnings Snapshot & Analysts Target Update on Athersys, Inc. (NASDAQ:ATHX)? - Wall Street Beacon (NASDAQ:ATHX)
wsbeacon.com - January 31 at 8:53 PM
News IconPeeling Back The Layers on Athersys, Inc. (NASDAQ:ATHX): Analysts & Street Weigh In - Wall Street Beacon (NASDAQ:ATHX)
wsbeacon.com - January 31 at 3:52 PM
insidermonkey.com logoAthersys, Inc. (ATHX) Down, Maybe An Opportunity? - Insider Monkey (blog) (NASDAQ:ATHX)
www.insidermonkey.com - January 31 at 3:52 PM
News IconAthersys, Inc. (ATHX) Down, Maybe An Opportunity? (NASDAQ:ATHX)
feedproxy.google.com - January 31 at 8:26 AM
News IconWalgreens and Rite Aid Agree to Cut Deal Price, Sell More Stores (NASDAQ:ATHX)
vgtoday.net - January 30 at 9:46 PM
News IconUnusual Volume Spikes For: Southwestern Energy Company (NYSE:SWN) (NASDAQ:ATHX)
flapship.com - January 30 at 9:46 PM
investopedia.com logoAthersys Launches $20M Public Offering (ATHX) (NASDAQ:ATHX)
www.investopedia.com - January 30 at 9:46 PM
News IconLookout for these Two stocks: Athersys, Inc. (NASDAQ:ATHX), Southwestern Energy Company (NYSE:SWN) - The Newburgh Press (NASDAQ:ATHX)
newburghpress.com - January 30 at 4:45 PM
News IconAthersys, Inc. (NASDAQ:ATHX) Quarterly EPS Projection At $-0.11 - Stock Observer (NASDAQ:ATHX)
www.thestockobserver.com - January 30 at 4:45 PM
marketexclusive.com logoAthersys, Inc. (NASDAQ:ATHX) Down, Maybe An Opportunity? - Market Exclusive (NASDAQ:ATHX)
marketexclusive.com - January 30 at 4:45 PM
investopedia.com logoAthersys Launches $20M Public Stock Offering (NASDAQ:ATHX)
www.investopedia.com - January 30 at 4:45 PM
streetinsider.com logoForm 424B5 ATHERSYS, INC / NEW (NASDAQ:ATHX)
www.streetinsider.com - January 29 at 8:40 PM
smarteranalyst.com logoAthersys, Inc. (ATHX) Prices 19.8 Million Shares at $1.01; Shares Fall 30% - Smarter Analyst (NASDAQ:ATHX)
www.smarteranalyst.com - January 29 at 1:43 AM
News IconNews Impact Score Of Athersys, Inc. (NASDAQ:ATHX) At 74 - Stock Observer (NASDAQ:ATHX)
www.thestockobserver.com - January 28 at 3:42 PM
News IconShares Hitting The Skids, Bounding Lower Mid-Day: Athersys, Inc. (NASDAQ:ATHX) - Wall Street Beacon (NASDAQ:ATHX)
wsbeacon.com - January 27 at 9:54 PM
News IconHigh Volatility Creating Buzz Mid-Session For Athersys, Inc. (NASDAQ:ATHX) - Wall Street Beacon (NASDAQ:ATHX)
wsbeacon.com - January 27 at 9:54 PM
News IconIs There Inherent Value in Athersys, Inc. (NASDAQ:ATHX)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:ATHX)
wsbeacon.com - January 27 at 9:54 PM
investing.com logoU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.04% (NASDAQ:ATHX)
www.investing.com - January 27 at 4:50 PM
us.rd.yahoo.com logo9:00 am Athersys prices underwritten public offering of 19,802,000 shares of its common stock at $1.01/share (NASDAQ:ATHX)
us.rd.yahoo.com - January 27 at 4:50 PM
News IconStock Momentum in Focus on Shares of Athersys Inc. (ATHX) - Sherwood Daily (NASDAQ:ATHX)
sherwooddaily.com - January 27 at 4:50 PM
streetinsider.com logoAthersys (ATHX) Prices 19.8M Shares at $1.01 - StreetInsider.com - StreetInsider.com (NASDAQ:ATHX)
www.streetinsider.com - January 27 at 4:50 PM
News IconEarnings in Full Force, Analysts Take Aim at Athersys, Inc. (NASDAQ:ATHX) - Wall Street Beacon (NASDAQ:ATHX)
wsbeacon.com - January 27 at 4:50 PM
finance.yahoo.com logoAthersys Announces Pricing of Public Offering of Common Stock (NASDAQ:ATHX)
finance.yahoo.com - January 27 at 4:50 PM

Social

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Where is Athersys' stock going? Where will Athersys' stock price be in 2017?

2 equities research analysts have issued 1 year target prices for Athersys' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Athersys' share price to reach $8.50 in the next twelve months.

When will Athersys announce their earnings?

Athersys is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:

  • Needham & Company LLC analysts commented, "Athersys is developing MultiStem, an off-the-shelf cell therapy that promotes tissue repair. The lead indication is ischemic stroke. Existing stroke treatments, which focus on removing the offending blood clot, can only be used in a short window of time, but MultiStem has shown efficacy in a longer time window (24-36 hours) and can thus address far more patients. Athersys' Japanese partner Healios will start a 220-patient pivotal trial shortly. Data is expected in mid-2018. While there is some controversy around the Phase II data, we believe the trial has a favorable risk:reward in what we see as a blockbuster opportunity. Initiate at Buy with a $7 price target." (2/7/2017)
  • According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (11/14/2016)

  • Maxim Group analysts commented, "On September 9, Sorrento presented at an industry conference in New York City. We had an additional meeting with CFO Kevin Herde." (9/12/2016)

Who owns Athersys stock?

Athersys' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Prudential PLC (2.51%), State Street Corp (1.31%), Russell Investments Group Ltd. (0.48%), Ladenburg Thalmann Financial Services Inc. (0.16%) and Oxford Asset Management (0.08%). Company insiders that own Athersys stock include Bokkelen Gil Van, Ismail Kola, John J Harrington, Kenneth H Traub, Laura K Campbell, Robert J Deans, William Lehmann Jr and William Lehmann, Jr.

Who sold Athersys stock? Who is selling Athersys stock?

Athersys' stock was sold by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc.. Company insiders that have sold Athersys stock in the last year include John J Harrington and William Lehmann Jr.

Who bought Athersys stock? Who is buying Athersys stock?

Athersys' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Prudential PLC, Oxford Asset Management and State Street Corp. Company insiders that have bought Athersys stock in the last two years include Ismail Kola, Kenneth H Traub and Laura K Campbell.

How do I buy Athersys stock?

Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Athersys stock cost?

One share of Athersys stock can currently be purchased for approximately $1.20.

Athersys (NASDAQ:ATHX) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Earnings History Chart

Earnings by Quarter for Athersys (NASDAQ:ATHX)

Dividend History Chart

Dividend Payments by Quarter for Athersys (NASDAQ:ATHX)

Last Updated on 2/27/2017 by MarketBeat.com Staff